Transgenic and pharmacological studies in mice have demonstrated the beneficial effects of MGAT inhibition as a therapy for treating several metabolic diseases, including obesity, insulin resistance, T2D, and NAFLD. The gene discussed is MGAT1; the disease is obesity due to melanocortin 4 receptor deficiency.